Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Nintedanib cut lung function decline in interstitial lung disease with systemic sclerosis

Publish date:: May 21, 2019

Key clinical point: The tyrosine kinase inhibitor nintedanib may be a useful treatment for interstitial lung disease associated with systemic sclerosis (SS-ILD).

Major finding: Nintedanib decreased the annual rate of lung function decline by 44% among patients with SS-ILD.

Study details: The randomized, placebo-controlled study comprised 576 patients.

Disclosures: The trial was sponsored by Boehringer Ingelheim. Dr. Distler is the primary investigator.

Citation:

Distler O et al. ATS 2019, Abstract A7360.

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

Weight loss may be paramount lifestyle change in preventing gout,

Gut microbiome influences response to methotrexate in new-onset RA patients,

Early treatment of RA with DMARDs promotes sustained remission,

Must Reads in Lupus & Connective Tissue Diseases

High-need, high-cost lupus patients described for first time,

Slow taper off antimalarial is best to avoid lupus flare during remission,

Sjögren’s symptom clusters may identify treatment options,

Transcutaneous VNS on the ear shows positive effects in lupus pilot trial,

ASSET extension supports abatacept as treatment for diffuse cutaneous systemic sclerosis,